<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Dipyridamole: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Dipyridamole: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Dipyridamole: Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="11633" href="/d/html/11633.html" rel="external">see "Dipyridamole: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13241" href="/d/html/13241.html" rel="external">see "Dipyridamole: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52866625"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Dipyridamole [DSC];</li>
<li>Persantine</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F161478"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antiplatelet Agent;</li>
<li>
                        Vasodilator</li></ul></div>
<div class="block doa drugH1Div" id="F161439"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0951f56b-dbb1-42fd-92a9-5f820d3fd36f">Evaluation of coronary artery disease, diagnostic agent</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Evaluation of coronary artery disease, diagnostic agent</b>
<b>: IV:</b> 0.56 mg/kg over 4 minutes; maximum dose: 70 mg/day. Following completion of dipyridamole infusion, inject radiotracer (eg, thallium-201) in 3 to 5 minutes. <b>Note:</b> To reverse complications and side effects of dipyridamole, aminophylline should be available for urgent/emergent use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26914678']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26914678'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990663"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">There are no dosage adjustment provided in manufacturer’s labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: Not dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26714677']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26714677'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987891"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustment provided in manufacturer’s labeling.</p></div>
<div class="block doo drugH1Div" id="F46367312"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> Dosing is not well established; it is customary to use weight-based doses up to a weight of 125 kg (maximum dose: 70 mg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26914678']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26914678'])">Ref</a></span>).</p></div>
<div class="block doe drugH1Div" id="F161440"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F161457"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13241" href="/d/html/13241.html" rel="external">see "Dipyridamole: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a47916bf-669f-4b42-bf00-02e8a4c1f0e0">Antiplatelet, general dosing</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Antiplatelet, general dosing:</b> Limited data available: Infants, Children, and Adolescents: Oral: 2 to 6 mg/kg/day in 3 divided doses; usual adult maximum dose: 100 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Park.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Park.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3d1c79ec-e547-4a6c-bf60-5bf0ab36bd7e">Antiplatelet, mechanical prosthetic heart valves</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Antiplatelet, mechanical prosthetic heart valves: Note:</b> Although FDA approved for this indication, expert recommendations do not include dipyridamole as a first-line option for thrombotic prophylaxis for mechanical prosthetic heart valves in pediatric patients; vitamin K antagonists with other antiplatelet agents (eg, low-dose aspirin) are recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315277','lexi-content-ref-22315272']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315277','lexi-content-ref-22315272'])">Ref</a></span>). Limited data available: Infants, Children, and Adolescents: Oral: 2 to 5 mg/kg/day in divided doses, most commonly in 3 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11157659','lexi-content-ref-Park.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11157659','lexi-content-ref-Park.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a2efa133-cedb-451f-a64b-dfdf9a123efa">Cardiac perfusion scans</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cardiac perfusion scans:</b> Limited data available: Children ≥6 years and Adolescents: IV: 0.56 mg/kg administered over 4 minutes; maximum adult dose: 70 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26914678','lexi-content-ref-28000002']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26914678','lexi-content-ref-28000002'])">Ref</a></span>). <b>Note:</b> To reverse complications and side effects of dipyridamole, aminophylline should be available for urgent/emergent use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26914678']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26914678'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d1f5df16-e5e7-4989-9670-a5ea7f40efb8">Proteinuria, adjunct therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Proteinuria (IgA nephropathy, Henoch-Schönlein purpura), adjunct therapy: </b>Limited data available: Children ≥7 years and Adolescents: Oral: Initial: 3 to 5 mg/kg/day in 3 divided doses; may titrate to reported range: 5 to 6 mg/kg/day in 3 divided doses; maximum daily dose: 400 mg/<b>day</b>; in trials dipyridamole was given as part of a 3 or 4 drug combination therapy (eg, immunosuppressant agents, antihypertensive agents, and an anticoagulant) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21493743','lexi-content-ref-12940609','lexi-content-ref-21203777','lexi-content-ref-18224343']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21493743','lexi-content-ref-12940609','lexi-content-ref-21203777','lexi-content-ref-18224343'])">Ref</a></span>). <b>Note:</b> Antiplatelet therapy is not recommended by national guidelines because efficacy results in trials cannot be directly associated with dipyridamole as opposed to the other agents in the drug regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-KDIGO.2012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-KDIGO.2012'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51094056"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, dipyridamole is likely not dialyzable secondary to high protein binding (99% protein bound).</p></div>
<div class="block dohp drugH1Div" id="F51094057"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F161403"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral</b>: Adverse reactions may include combination therapy with warfarin.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Nervous system: Dizziness (14%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distress (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (2%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Flushing</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea, vomiting</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Angina pectoris (≤20%), chest pain (≤20%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (12%), headache (12%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Extrasystoles (5%), flushing (3%), hypertension (2%), hypotension (5%), ST segment changes on ECG (8%), tachycardia (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dyspepsia (1%), nausea (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (1%), pain (3%), paresthesia (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (3%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction, atrial fibrillation, atrioventricular block, bradycardia, cardiac arrhythmia, cardiomyopathy, ECG abnormality, edema, heart block, intermittent claudication, orthostatic hypotension, palpitations, supraventricular tachycardia, syncope, ventricular arrhythmia, ventricular tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased thirst</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, dysgeusia, dysphagia, eructation, flatulence, increased appetite, tenesmus, vomiting, xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Mastalgia, perineal pain</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction (including pain at injection site)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety, asthenia, ataxia, depersonalization, drowsiness, hypertonia, hypoesthesia, malaise, migraine, nervousness, tremor, vertigo, voice disorder</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, back pain, lower limb cramp, muscle rigidity, myalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Eye pain, visual disturbance</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Otalgia, tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Renal pain</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm, cough, hyperventilation, pharyngitis, pleuritic chest pain, rhinitis</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Ventricular fibrillation</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Seizure, transient ischemic attacks</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (any formulation):</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Asystole, shock (Dioverti 2011), sinus node dysfunction (arrest and depression) (Khalili 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Cholelithiasis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic failure, hepatic impairment, hepatitis, increased liver enzymes</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (including anaphylaxis, angioedema, and nonimmune anaphylaxis) (Weinmann 1994)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Cerebrovascular accident (Whiting 1993)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthritis</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Laryngeal edema, pulmonary edema (Dioverti 2011)</p></div>
<div class="block coi drugH1Div" id="F161417"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to dipyridamole or any component of the formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Injection: shock; circulatory collapse.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the American Society of Nuclear Cardiology (ASNC) the following are additional contraindications for dipyridamole stress testing (ASNC [Henzlova 2016]): Bronchospastic lung disease with ongoing wheezing or history of significant reactive airway disease; systolic BP &lt;90 mm Hg; uncontrolled hypertension (systolic BP &gt;200 mm Hg or diastolic BP &gt;110 mm Hg); ingestion of caffeinated foods or beverages within the last 12 hours; unstable angina, acute coronary syndrome, or myocardial infarction within 2 to 4 days. Relative contraindications include: Heart rate &lt;40 beats/minute; second- or third-degree heart block without a pacemaker; severe aortic stenosis; seizure disorder (cannot receive aminophylline).</p></div>
<div class="block war drugH1Div" id="F161400"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with hypotension, unstable angina, and/or recent myocardial infarction; may enhance exercise induced myocardial ischemia in patients with chronic stable angina.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Antiplatelet agents/anticoagulants: Use with caution in patients on other antiplatelet agents or anticoagulation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pharmacologic stress testing: Interrupt oral dipyridamole therapy for 48 hours prior to stress testing with adenosine, IV dipyridamole, or regadenoson; may increase risk for cardiovascular adverse effects and impair the test sensitivity.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Injection: Severe adverse reactions have occurred rarely with IV administration. Use the IV form with caution in patients with bronchospastic disease or unstable angina. Have aminophylline ready in case of urgency or emergency with IV use.</p></div>
<div class="block foc drugH1Div" id="F161411"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg/mL (10 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg, 50 mg, 75 mg</p></div>
<div class="block geq drugH1Div" id="F161396"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F161419"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Dipyridamole Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg/mL (per mL): $2.38</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Dipyridamole Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $0.26 - $1.42</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $0.47 - $2.29</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">75 mg (per each): $0.62 - $3.06</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866626"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Persantine: 5 mg/mL (10 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg/mL (2 mL, 10 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg [DSC], 50 mg [DSC], 75 mg [DSC]</p></div>
<div class="block adm drugH1Div" id="F855061"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IV: Infuse diluted solution over 4 minutes.</p></div>
<div class="block admp drugH1Div" id="F52612591"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer without regard to meals.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Infuse diluted solution over 4 minutes.</p></div>
<div class="block use drugH1Div" id="F161413"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Evaluation of coronary artery disease, diagnostic agent </b>
<b>(IV):</b> Diagnostic agent for evaluation of coronary artery disease.</p></div>
<div class="block mst drugH1Div" id="F161486"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Dipyridamole may be confused with disopyramide</p>
<p style="text-indent:-2em;margin-left:4em;">Persantine may be confused with Periactin</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Dipyridamole (oral, short-acting formulation; does not apply to the extended-release combination with aspirin) is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to its potential for causing orthostatic hypotension and availability of more effective alternatives. Of note, dipyridamole intravenous is acceptable for use in cardiac stress testing (Beers Criteria [AGS 2023]).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Persantine [US, Canada, Belgium, Denmark, France] may be confused with Permitil brand name for sildenafil [Argentina]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F9837685"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F161405"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase Inhibitors: Dipyridamole may diminish the therapeutic effect of Acetylcholinesterase Inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Adenosine: Dipyridamole may enhance the adverse/toxic effect of Adenosine. Specifically, cardiovascular effects of adenosine may be enhanced. Adenosine dose reduction may be needed.  Management: For patients requiring pharmacologic stress testing with adenosine, hold dipyridamole tablets for 48 hours. Hold aspirin/dipyridamole capsules for 24 to 48 hours. For treatment of SVT, monitor for prolonged adenosine effects, consider lower initial doses.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers: Dipyridamole may enhance the bradycardic effect of Beta-Blockers. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Inhibitors of Equilibrative Nucleoside (ENT1) and Concentrative Nucleoside (CNT3) Transport Proteins may increase the serum concentration of Cladribine.  Management: Avoid concomitant use of ENT1 or CNT3 inhibitors during the 4 to 5 day oral cladribine treatment cycles whenever possible. If combined, consider an ENT1 or CNT3 inhibitor dose reduction and separation in the timing of administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desirudin: Dipyridamole may enhance the adverse/toxic effect of Desirudin. Specifically, the risk of bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Enoxaparin: Dipyridamole may enhance the adverse/toxic effect of Enoxaparin. Specifically, the risk of bleeding may be increased.  Management: If possible, discontinue dipyridamole prior to initiating enoxaparin. If coadministration is unavoidable, monitor closely for clinical and laboratory evidence of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparin: Dipyridamole may enhance the adverse/toxic effect of Heparin. Specifically, the risk of bleeding may be increased.  Management: Use caution and reduce the dose of heparin or dipyridamole if these agents are combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phenindione: Dipyridamole may enhance the adverse/toxic effect of Phenindione. Specifically, the risk of bleeding may be increased.  Management: Avoid coadministration of dipyridamole and phenindione if possible. If coadministration is required, monitor closely for clinical and laboratory evidence of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Regadenoson: Dipyridamole may enhance the adverse/toxic effect of Regadenoson. Specifically, adenosine mediated effects may be enhanced.  Management: Avoid dipyridamole for 48 hours prior to the administration of regadenoson when possible.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Riociguat: Dipyridamole may enhance the hypotensive effect of Riociguat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tinzaparin: Dipyridamole may enhance the adverse/toxic effect of Tinzaparin. Specifically, the risk of bleeding may be increased. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F161420"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events  have not been observed in animal reproduction studies. </p></div>
<div class="block brc drugH1Div" id="F161421"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">Dipyridamole is excreted in breast milk. The manufacturer recommends that caution be exercised when administering dipyridamole to breastfeeding patients.</p></div>
<div class="block mop drugH1Div" id="F161409"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">IV: During stress perfusion imaging, monitor blood pressure, heart rate, ECG, respiration. Monitor for signs of poor perfusion (pallor, cyanosis, cold skin) (ASNC [Henzlova 2016])</p></div>
<div class="block pha drugH1Div" id="F161399"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits the activity of adenosine deaminase and phosphodiesterase, which causes an accumulation of adenosine, adenine nucleotides, and cyclic AMP; these mediators then inhibit platelet aggregation and may cause vasodilation; may also stimulate release of prostacyclin or PGD<sub>2</sub>; causes coronary vasodilation</p></div>
<div class="block phk drugH1Div" id="F161416"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Readily, but variable </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: Adults: V<sub>d</sub>: 2-3 L/kg </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: 91% to 99% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic to glucuronide conjugate </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Terminal: 10-12 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, serum: 2-2.5 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Feces (as glucuronide conjugates and unchanged drug)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F2869376"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Persantin</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Maxicardil | Persantin</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Persantin</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Persantin</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Coribon | Coroxin | Pyrintin | Santinal mr</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Coronair | Dipyridamole Eurogenerics | Dipyridamole teva generics belgium | Dipyridan | Docdipyri | Persantine</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Antistenocardin | Biocardin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Persantin</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Persantin</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Dipiridamol | Persantin | Ticinil</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Ai ke xin | Dipyridamole and sodium chloride | Sheng da</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Dipiridamol | Persantin</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Curantyl N | Dipiridamol | Persantin</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Persantin</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Persantin</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Dipiridamol | Persantin</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Persantin</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Curantyl | Dipyridamole actavis | Penselin | Persantin</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Anaplate | Persantin | Pressavein</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Persantin</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Atrombin | Dipycal | Dipyrin | Persantin</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Cleridium | Diphar | Perkod | Persantine | Prandiol | Protangix</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Attia | Cerebrovase | Dipyridamole aps | Dipyridamole berk | Dipyridamole cox | Dipyridamole dc | Dipyridamole kent | Modaplate | Ofcram PR | Persantin | Vasyrol</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Adezan | Persantin</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo dipyridamole | Dimol | Dipridamole | Lidamole | Persantin | Pymotin</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Persantin</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Curantyl</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Cardial | Cortab | Depymol | Dilacor | Persantin | Vasodamol | Vasokor | Vasotin</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Attia | Persantin</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Cardoxin</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Deplatol | Dynacard | Persantin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Corosan | Dipiridamolo provvisoria | Persantin</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Adezan | Antiplate | Persantin</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Adlease | Agilease | Anginal | Antwarle | Astmol | Atlantin s.s. seiyaku | Atlantin towa | Calcora | Carmiosin | Coronamole | Dattoriena | Dipertin | Dipyramole | Dipyramole choseido | Dipyridamole kobayashi | Dipyridamole nichiiko | Dipyridamole okura | Dipyridamole seiko | Dipyridamole showa | Dipyridamole tsuruhara | Dipyridan | Dluck | Faster ohara | Faster wakodo | Gulliostin | Healthohra | Healthside | Heltudol | Jibital | Kucore | Metropolyn | Microbamol taiyo | Nichiridamol | Pectoragine | Pelpalin | Penselin | Pentalate | Percystan | Perismol | Permiltin merck hoei | Permiltin zensei | Persantin | Pidimidole | Piridamotin | Piridantin | Piroan | Prositel | Pyrisatin | Riporsine | Risatirin hexal | Rucus | Runapyran | Rupenol kobayashi kako | Rupenol merck hoei | Sanpell | Santhimon | Shiphnos | Synthelol | Takakisan | Tinol | Tohmol | Youridamole | Youridamole sankyo</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Centermol | Dimole | Dipiramol | Dipyramole | Diramol | Pegamol | Penetran | Peridamol | Persantin | Radmol</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Persantin</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Apo dipyridamole | Perkod | Persantine</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Antistenocardin | Apo dipyridamole | Attia | Curantyl | Dipiridamol | Persantin | Thrombonil</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Dipyridamole Eurogenerics | Persantine</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Antistenocardin | Apo dipyridamole | Curantyl | Dipiridamol | Penselins | Persantin | Procardin | Thrombonil</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Cleridium | Persantine</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Digal | Persantin | Trepol | Trompersantin</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Apo dipyridamole | Dipymol | Persantin</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Dipyridamol | Dipyridamol Alpharma | Dipyridamol CF | Dipyridamol PCH | Persantin | Persantine</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Aponova | Dipyridamol | Persantin</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Dipyridamole actavis | Persantin | Pytazen</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Dipiridamol | Persantin</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Angicor | Dipyridamole Pacific | Esvidil | Mersandien | Persantin | Prexin | Ridamol | Sanper</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Cleridium | Damopres | Persantin</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Anginal | Curantyl N | Persantin</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Persantine</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Persantin | Proxicor</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Curantyl | Dipiridamol | Dipiridamol zentiva</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Apo dipyridamole | Curantil | Curantyl | Curantyl N | Dipiridamol | Dipyridamol | Parsedyl | Persantin | Sanomyl Sanovel | Thrombonil | Vero dipiridamol</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Antiplate | Apo dipyridamole | Persantin</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Dipyridamol alternova | Dipyridamol fermenta | Persantin</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Apo dipyridamole | Perazodin | Persantin | Procardin</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Persantin</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Curantyl N</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Agremol | Persantin | Posanin</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Cleridium | Perkod | Persantine | Procardin</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Drisentin | Kardisentin | Persantin | Trodamol | Tromboliz | Trombostaz | Vazodil</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Angimole | Anginal | Anginar | Carditonin | Cleridium | Corodil | Corosan | Coroxin | Corsintin | Counthin | Cyasin | Dicorol | Dimole | Dipyridan | Easying | Efosin | Fulcin | Helzin | Lidamole | Parotin | Pectrin | Pensaline | Penselin | Peransin | Percotin | Perdamole | Perisin | Peritin | Persantin | Persantine | Persatin | Persine | Pesadin | Peysan | Piroan | Poshinlen | Posintin | Potosintin | Pydamole | Pyridamol | Rupenol | Sancin | Sandel | Shinmiochien | Since | Solantin | Sunmegen | Suzin | Uginin | Unisin | Vasonin | Vasotin | Wnshinlien</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Curantyl | Curantyl N | Dipiridamol | Persantin</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Clinicor | Deplaskin | Parneril | Percordin | Persantin | Ridamol</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Megalis | Meranol | Persantin | Precar</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Persantin | Plato</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dipyridamole-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15289388">
<a name="15289388"></a>Antman EM, Anbe SC, Alpert JS, et al, “ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction - Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction),” <i>Circulation</i>, 2004, 110(5):588-636.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dipyridamole-drug-information/abstract-text/15289388/pubmed" id="15289388" target="_blank">15289388</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21640290">
<a name="21640290"></a>Bell AD, Roussin A, Cartier R, et al, “The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines,” <i>Can J Cardiol</i>, 2011, 27(Suppl A):1-59.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dipyridamole-drug-information/abstract-text/21640290/pubmed" id="21640290" target="_blank">21640290</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21672887">
<a name="21672887"></a>Dioverti M, Fishman R, Moskowitz R, et al. Dipyridamole-associated shock and pulmonary edema. <i>Ann Pharmacother</i>. 2011;45(7-8):e42. doi:10.1345/aph.1P734<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dipyridamole-drug-information/abstract-text/21672887/pubmed" id="21672887" target="_blank">21672887</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Dipyridamole [prescribing information]. Birmingham, AL: Oxford Pharmaceuticals; January 2021.</div>
</li>
<li>
<div class="reference">
                  Dipyridamole injection [prescribing information]. Lake Forest, IL: Hospira; 2024.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23098967">
<a name="23098967"></a>Ferraris VA, Saha SP, Oestreich JH, et al, “2012 Update to the Society of Thoracic Surgeons Guideline on Use of Antiplatelet Drugs in Patients Having Cardiac and Noncardiac Operations,” <i>Ann Thorac Surg</i>, 2012, 94(5):1761-81.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dipyridamole-drug-information/abstract-text/23098967/pubmed" id="23098967" target="_blank">23098967</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26714677">
<a name="26714677"></a>Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al. Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. <i>Neurocrit Care.</i> 2016;24(1):6-46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dipyridamole-drug-information/abstract-text/26714677/pubmed" id="26714677" target="_blank">26714677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315257">
<a name="22315257"></a>Guyatt GH, Akl EA, Crowther M, et al, “Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,” <i>Chest</i>, 2012, 141(2 Suppl):7-47.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dipyridamole-drug-information/abstract-text/22315257/pubmed" id="22315257" target="_blank">22315257</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26914678">
<a name="26914678"></a>Henzlova MJ, Duvall WL, Einstein AJ, Travin MI, Verberne HJ. ASNC imaging guidelines for SPECT nuclear cardiology procedures: stress, protocols, and tracers. <i>J Nucl Cardiol.</i> 2016;23(3):606-639. doi:10.1007/s12350-015-0387-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dipyridamole-drug-information/abstract-text/26914678/pubmed" id="26914678" target="_blank">26914678</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21493743">
<a name="21493743"></a>Kamei K, Nakanishi K, Ito S, et al. Long-term results of a randomized controlled trial in childhood IgA nephropathy. Long-term results of a randomized controlled trial in childhood IgA nephropathy. <i>Clin J Am Soc Nephrol</i>. 2011;6(6):1301-1307.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dipyridamole-drug-information/abstract-text/21493743/pubmed" id="21493743" target="_blank">21493743</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12940609">
<a name="12940609"></a>Kano K, Nishikura K, Yamada Y, Arisaka O. Effect of fluvastatin and dipyridamole on proteinuria and renal function in childhood IgA nephropathy with mild histological findings and moderate proteinuria. <i>Clin Nephrol</i>. 2003;60(2):85-89.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dipyridamole-drug-information/abstract-text/12940609/pubmed" id="12940609" target="_blank">12940609</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36815960">
<a name="36815960"></a>Khalili M, Jahani M. Atrioventricular (AV) block and sinus arrest associated with dipyridamole infusion. <i>ARYA Atheroscler</i>. 2022;18(3):1-3. doi:10.48305/arya.v18i0.2381<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dipyridamole-drug-information/abstract-text/36815960/pubmed" id="36815960" target="_blank">36815960</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KDIGO.2012">
<a name="KDIGO.2012"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. <i>Kidney Int. Suppl.</i> 2012;139-274.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315273">
<a name="22315273"></a>Lansberg MG, O'Donnell MJ, Khatri P, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i>. 2012;141(2 Suppl):e601S-636S.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dipyridamole-drug-information/abstract-text/22315273/pubmed" id="22315273" target="_blank">22315273</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315277">
<a name="22315277"></a>Monagle P, Chan AKC, Goldenberg NA, et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i>. 2012;141(2 Suppl):e737S-e801S.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dipyridamole-drug-information/abstract-text/22315277/pubmed" id="22315277" target="_blank">22315277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11157659">
<a name="11157659"></a>Monagle P, Michelson AD, Bovill E, et al, “Antithrombotic Therapy in Children,” <i>Chest</i>, 2001, 119(1 Suppl):344S-370S.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dipyridamole-drug-information/abstract-text/11157659/pubmed" id="11157659" target="_blank">11157659</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21203777">
<a name="21203777"></a>Ninchoji T, Kaito H, Nozu K, et al. Treatment strategies for Henoch-Schönlein purpura nephritis by histological and clinical severity. <i>Pediatr Nephrol</i>. 2011;26(4):563-569.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dipyridamole-drug-information/abstract-text/21203777/pubmed" id="21203777" target="_blank">21203777</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33332150">
<a name="33332150"></a>Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. <i>Circulation</i>. 2021;143(5):e72-e227. doi:10.1161/CIR.0000000000000923<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dipyridamole-drug-information/abstract-text/33332150/pubmed" id="33332150" target="_blank">33332150</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Park.1">
<a name="Park.1"></a>Park MK. <i>Park's Pediatric Cardiology for Practitioners</i>. 6th ed. Philadelphia, PA: Elsevier Health Sciences; 2014.</div>
</li>
<li>
<div class="reference">
                  Persantine (dipyridamole) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; December 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Persantine.2">
<a name="Persantine.2"></a>Persantine (dipyridamole) [product monograph]. Milton, Ontario, Canada: McKesson Specialized Distribution Inc; August 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2712632">
<a name="2712632"></a>Rao PS, Solymar L, Mardini MK, et al, “Anticoagulant Therapy in Children With Prosthetic Valves,” <i>Ann Thorac Surg</i>, 1989, 47(4):589-92.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dipyridamole-drug-information/abstract-text/2712632/pubmed" id="2712632" target="_blank">2712632</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7633022">
<a name="7633022"></a>Stanek EJ, Melko GP, and Charland SL, "Xanthine Interference With Dipyridamole-Thallium-201 Myocardial Imaging," <i>Ann Pharmacother</i>, 1995, 29(4):425-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dipyridamole-drug-information/abstract-text/7633022/pubmed" id="7633022" target="_blank">7633022</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15383486">
<a name="15383486"></a>Stein PD, Schunemann HJ, Dalen JE, et al, “Antithrombotic Therapy in Patients With Saphenous Vein and Internal Mammary Artery Bypass Grafts: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy,” <i>Chest</i>, 2004, 126(3 Suppl):600-08.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dipyridamole-drug-information/abstract-text/15383486/pubmed" id="15383486" target="_blank">15383486</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3785481">
<a name="3785481"></a>Ueda N, Kawaguchi S, Niinomi Y, et al, “Effect of Dipyridamole Treatment on Proteinuria in Pediatric Renal Disease,” <i>Nephron</i>, 1986, 44(3):174-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dipyridamole-drug-information/abstract-text/3785481/pubmed" id="3785481" target="_blank">3785481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34453165">
<a name="34453165"></a>Vahanian A, Beyersdorf F, Praz F, et al; ESC/EACTS Scientific Document Group. 2021 ESC/EACTS guidelines for the management of valvular heart disease. <i>Eur Heart J</i>. 2022;43(7):561-632. doi:10.1093/eurheartj/ehab395<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dipyridamole-drug-information/abstract-text/34453165/pubmed" id="34453165" target="_blank">34453165</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18323511">
<a name="18323511"></a>Verro P, Gorelick PB, Nguyen D, et al. Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: a meta-analysis. <i>Stroke</i>. 2008;39(4):1358-1363.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dipyridamole-drug-information/abstract-text/18323511/pubmed" id="18323511" target="_blank">18323511</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28000002">
<a name="28000002"></a>Vijarnsorn C, Noga M, Schantz D, Pepelassis D, Tham EB. Stress perfusion magnetic resonance imaging to detect coronary artery lesions in children. <i>Int J Cardiovasc Imaging</i>. 2017;33(5):699-709.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dipyridamole-drug-information/abstract-text/28000002/pubmed" id="28000002" target="_blank">28000002</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7977438">
<a name="7977438"></a>Weinmann P, Moretti JL, Leynadier F. Anaphylaxis-like reaction induced by dipyridamole during myocardial scintigraphy. <i>Am J Med</i>. 1994;97(5):488. doi:10.1016/0002-9343(94)90331-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dipyridamole-drug-information/abstract-text/7977438/pubmed" id="7977438" target="_blank">7977438</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8418253">
<a name="8418253"></a>Whiting JH Jr, Datz FL, Gabor FV, Jones SR, Morton KA. Cerebrovascular accident associated with dipyridamole thallium-201 myocardial imaging: case report. <i>J Nucl Med</i>. 1993;34(1):128-130.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dipyridamole-drug-information/abstract-text/8418253/pubmed" id="8418253" target="_blank">8418253</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315272">
<a name="22315272"></a>Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH. Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i>. 2012;141(2 Suppl):e576S-e600S.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dipyridamole-drug-information/abstract-text/22315272/pubmed" id="22315272" target="_blank">22315272</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18224343">
<a name="18224343"></a>Yoshikawa N, Nakanishi K, Ishikura K, et al. Combination therapy with mizoribine for severe childhood IgA nephropathy: a pilot study. <i>Pediatr Nephrol</i>. 2008;23(5):757-763.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dipyridamole-drug-information/abstract-text/18224343/pubmed" id="18224343" target="_blank">18224343</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9377 Version 343.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
